Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOPDAPT-2 ACS: 1-Month DAPT in ACS
NCT03462498Phase 4Active, not recruiting
- Sponsor
- Kyoto University
- Start
- Apr 2018
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of clopidogrel in acute coronary syndrome (ACS) (2 arms), sponsored by Kyoto University. Primary endpoints: Composite of cardiovascular death, myocardial infarction, definite stent thrombosis, stroke, or TIMI major/minor bleeding at 12 months and Composite of cardiovascular death, myocardial infarction, definite stent thrombosis, stroke, or TIMI major/minor bleeding (60 months). Started Apr 2018; status: active, not recruiting.
02
Drugs
clopidogrel
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT03462498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03462498.